BCG Vaccine Market

Global BCG Vaccine Market Size (2024 to 2029)

The size of the global BCG vaccine market is predicted to reach USD 65.02 Billion by 2029 from USD 50.7 billion in 2024, growing at a CAGR of 5.1% from 2024 to 2029.

Tuberculosis can result in death, due to which the adoption and demand for BCG vaccines have grown significantly over the last several years. The need for BCG vaccine is more in regions where TB incidence is higher, and access to TB treatments is less. The BCG vaccine is also believed to help fight against other infectious diseases. However, there is no concrete evidence to say that.

Albert Calmette and Camille Guérin produced the original strain of BCG in 1924 at the Pasteur Institute. BCG vaccine is used against Tuberculosis. Tuberculosis is a severe infection, which causes by the lungs, sometimes in other parts of the body. Vaccine Dose is given to healthy babies after birth because, at that age, they are at high risk of getting immunized. The Bacille Calmette-Guerin vaccine is one of the most widely used current vaccines. It is a part of the national childhood immunization program. The BCG vaccine included types that are Immune BCG and Therapy BCG. BCG vaccine is also used to treat other mycobacterial infections, such as Buruli ulcer diseases. The World Health Organization (WHO) estimates that TB caused to 10 million people and claimed 1.6 million lives in 2017.

Global BCG Vaccine Market Drivers:

The growing incidence of TB and increasing support from various governments in favor of the BCG vaccine are expected to boost the market growth. The governments of various countries have supported the market for BCG vaccines in a variety of ways. Several governments have taken numerous measures to spread awareness regarding the importance of BCG vaccines and promote the accessibility to the vaccines in low- and middle-income countries, especially where TB is more prevalent. For instance, only 86% of infants worldwide received the BCG vaccine in 2020, and the unavailability of the BCG vaccine was still noticed in some areas, especially the vaccine’s accessibility is poor in the regions where the TB burden is high, which says the accessibility of BCG vaccine must improve further. In addition, many governments and health authorities have been investing significant amounts in the R&D, distribution, and administration of BCG vaccines and such initiatives are expected to share a favorable impact on market growth. For instance, the government of U.S. allocated USD 406 million in FY 2023, which was USD 233 million in FY 2013 for global TB control programs. On the other hand, the European Union funded the TBVAC2020 project and gave €22 million for the innovation and development of new vaccines for TB.

In addition, the growing adoption of technological advancements is predicted to fuel the growth rate of the BCG vaccine market. Technological developments have helped to improve the vaccine’s effectiveness and develop new and advanced vaccines. According to studies, technological advancements have contributed an estimated 15% of the improvement in the effectiveness of BCG vaccines and further aided in the development of new formulations. An increasing awareness among people regarding the severity of TB and the importance of vaccination is expected to promote the growth of the BCG vaccines market. Over the past 5 years, the growing awareness of the severity of TB among people has resulted in a 20% increase in demand for BCG vaccines worldwide.

Furthermore. the demand for BCG vaccine is increasing daily, with the rising birth rate population. Also, the spread rate of Tuberculosis in the adult stage of the community will boost the demand for BCG vaccines in the coming days. Therefore, stage-wise vaccines for Tuberculosis have a higher need in the future. For instance, the global birth rate is expected to grow by 1.1% annually worldwide, which is estimated to bring a considerable increase in the demand for BCG vaccines owing to the newborn vaccination programs. The increasing epidemic of diseases in the future can decide the rising demand for the BCG Vaccine and BCG vaccine pipeline evolution, which will influence supply and demand dynamics. 

Global BCG Vaccine Market Restraints:

The issues associated with the continuous supply of BCG vaccine, the scarcity of skilled professionals, and the lack of proper healthcare infrastructure in some countries are anticipated to impact the market growth during the forecast period. In addition, underdeveloped and developing countries are suffering from a shortage of BCG vaccines, which is expected to inhibit the growth rate of the worldwide market.

Impact of COVID-19 on the global BCG vaccine market:

COVID-19 has disrupted the global economy drastically. The World Health Organization (WHO) declared COVID-19 as a pandemic that has spread to around 203 countries globally. The lockdown has affected many industries in several ways; some industries were impacted badly, and some gained profits. The Bacillus Calmette-Gurin (BCG) Vaccine Market has seen some profits. The BCG vaccine is used to prevent Tuberculosis (TB), but some researchers have announced that the BCG vaccine can be used for COVID treatment, fuelling the market. However, the BCG vaccine is not a perfect cure for COVID-19; it is just used as an immediate medication to prevent deaths. All the COVID-19-affected older people got vaccinated in countries like India, which propelled the BCG vaccine market. Few countries have done clinical trials on humans to see the BCG vaccine's effectiveness, boosting market growth. These factors helped the BCG vaccine market grow during the COVID-19 pandemic. The key players in the market have done a great job by increasing BCG vaccine production during the pandemic.

REPORT COVERAGE:

This research report on the global BCG vaccine market has been segmented and sub-segmented based on demography, product type, application, end-user, and region.

Global BCG Vaccine Market - By Demographics:

• Pediatrics (0-18 years)
• Adults (19-35 years)

Based on demography, the paediatrics segment is a clear market leader and accounted for more than three-quarters of the global market share and is likely to retain the leading spot in the global market throughout the forecast period. BCG vaccine is infused in children in many countries after the months of lactation. In addition, the vaccine is compulsory for infants in countries where there is a prevalence of TB. Hence, the pediatrics segment leads the market in all countries. For instance, an estimated 100 million doses of BCG vaccines are being administered to pediatrics worldwide every year. In addition, the increasing funding from various governments to conduct R&D around the BCG vaccine and a growing number of awareness programs to promote awareness is expected to fuel the segment’s growth rate. Countries such as India, China and Brazil are particular about National Immunization Programs and these programs are driving the demand for BCG vaccines among the pediatrics. Furthermore, the rising birth rate worldwide is expected to contribute to segmental growth.

The adults segment is expected to grow steadily during the forecast period.

Global BCG Vaccine Market - By Product Type:

• Immune BCG 
• Therapy BCG

Based on product type, the immune BCG segment led the market in 2023 and accounted for 69.8% of the worldwide market share. The immune BCG segment is expected to continue to lead the market during the forecast period. It is because BCG vaccination has become mandatory in most countries as part of the national immunization program. Moreover, the vaccine's efficacy is reduced if not administered in infancy. Therefore, the usage of this vaccine is highest in Kenya. Polio and hepatitis B vaccines are usually administered alongside it.

Global BCG Vaccine Market - By End User:

• Pediatric 
• Adults 

Global BCG Vaccine Market - By Application:

• Home
• Commercial 

Based on the application, the commercial segment had 60.9% of the global market share in 2023 and is predicted to continue to dominate the market during the forecast period owing to the growing administering of BCG vaccines in hospitals to infants. Governments have also been procuring vaccine candidates on a large scale. The commercial settings are equipped with the latest medical equipment and trained healthcare professionals, due to which the preference of people to have the BCG vaccination at hospitals and clinics has increased.

However, the home segment accounted for a relatively smaller share of the worldwide market in 2023 and is expected to grow consistently during the forecast period owing to the growing preference from people to have the vaccination from the comfort of their homes.

Global BCG Vaccine Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The APAC BCG Vaccine Market accounted for the major share of the worldwide market in 2023. The APAC market is also expected to have promising occupancy in the global market during the forecast period. The incidence of TB is high among the countries of the APAC region, which is one of the major factors contributing to the regional market growth. The presence of a large population and growing birth rate in the APAC countries such as India and China are expected to demand a greater number of BCG vaccines, which is expected to promote regional market growth. In addition, the growing number of vaccination initiatives from the APAC governments is predicted to boost the market’s growth rate in APAC.

Furthermore, the availability of increased funding to conduct R&D of BCG vaccines and robust vaccine storage and distribution networks across the APAC region further propel the regional market growth. At the same time, Asia Pacific is expected to grow with the highest CAGR due to TB eradication campaigns in developing countries. As a result, Asia Pacific is the second most lucrative market for BCG vaccines; due to tropical lying countries like India, Japan, and Malaysian countries, TB prevalence is more in this region; around 40% of the world's TB population lies in this region. As a result, this provides ample scope for the BCG vaccine market to expand in this region.

The North American BCG Vaccine Market is a potential market worldwide and is anticipated to showcase a healthy CAGR in the coming years. The regional market's growth can be attributed to sophisticated healthcare and government policies toward eradicating TB. Though the prevalence of TB is less in this region, proper care and vaccination are taking place. Eastern EU region with Germany has more TB prevalence rate, and there is more market for the BCG vaccine market.

In the Latin American BCG Vaccine Market, countries like Brazil and Argentina are promising markets for the BCG vaccine market, as the TB prevalence rate in these regions is high.

The Middle East and Africa BCG Vaccine Market, especially the African continent, is a breeder house for Tuberculosis, and many countries, along with WHO, have framed many TB eradication programs. Hence, they provide a large market for the BCG vaccine. In the Middle East, Gulf countries have framed TB eradication programs to secure the people with transmission from Africa; these countries also contribute to the market to expand further in this region.

KEY MARKET PARTICIPANTS:

Some of the notable companies operating in the global BCG vaccine market profiled in the report are Merck & Co., Inc, Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd, InterVax Ltd, GreenSignal Bio Pharma Limited (GSBPL), Statens Serum Institute

RECENT MARKET DEVELOPMENTS:

• In January 2023, the World Health Organization (WHO) announced the launch of the TB Vaccine Accelerator Council. The major purpose of the council is to quicken the licensing and efficacy of novel TB vaccines by coordinating various parties involved in the development and usage of vaccines.
• In March 2021, by taking the help of South Korea, the TB Alliance launched an initiative called LIFT-TB. LIFT-TB stands for Leveraging Innovation for Faster Treatment of Tuberculosis. The major purpose of this initiative is to quicken the R&D of TB treatments by providing the required funding and other support.